Citigroup’s Protagonist Therapeutics PTGX Stock Holding History

Citigroup’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-25,400	Closed	-$584K	–	5691
2023 Q1	$584K	Buy	+25,400	New	+$427K	﹤0.01%	3008

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Citigroup's PTGX Position: Q2 2026 in Review

Citigroup increased its Protagonist Therapeutics (PTGX) stake by 25% in Q2 2026, buying an estimated $4.17M and bringing the position to 198,668 shares worth $24.4M. The position accounts for 0.01% of the portfolio, ranked #1060.

Citigroup first reported a position in PTGX in Q3 2016 and has held it in 37 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Citigroup held 198,668 shares of Protagonist Therapeutics worth $24.4M as of Q2 2026.
Citigroup bought 39,957 Protagonist Therapeutics shares in Q2 2026, an estimated $4.17M.
Protagonist Therapeutics made up 0.01% of Citigroup's portfolio in Q2 2026, its #1060 holding.
Citigroup first reported a position in Protagonist Therapeutics in Q3 2016 and has held it in 37 quarters since.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.